Brii Biosciences Limited(HK:2137)
HK$0.97-0.01 (-0.51%)
HK:2137
Brii Biosciences Limited stock drug pipeline
HK$0.97
At close:-0.01 (-0.51%)
Want to see HK:2137 full AI Analyst Report?
Brii Biosciences Limited (2137) Drug Pipeline
3 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Brii-835 (Vir-2218), Brii-179, Peg-Ifnα | Chronic Hepatitis B Virus (Hbv) Infection | Phase II | Recruiting | A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) | Oct 12, 2024 | ― |
| Brii-835 (Vir-2218), Brii-179, Peg-Ifnα | For Treatment Of Chronic Hepatitis B Virus Infection | Phase II | Active Not Recruiting | Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | Jun 28, 2024 | ― |
| Brii-296, Depo Medrol | Severe Postpartum Depression | Phase II | Completed | A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD) | Sep 21, 2023 | ― |
| Peg-Ifnα, Brii-835 | Chronic Hepatitis B Virus Infection | Phase II | Active Not Recruiting | Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients | Jul 21, 2023 | ― |
| Brii-297 | Postpartum Depression | Phase I | Completed | A Study of BRII-297 in Healthy Adult Subjects | Apr 12, 2023 | ― |
| Brii-196 And Brii-198 | Covid-19 | Phase II | Completed | A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 | Mar 04, 2021 | ― |
| Brii-835 (Vir-2218), Brii-179 (Vbi-2601) With Ifn-Α, Brii-179 (Vbi-2601) | Hepatitis B, Chronic | Phase II | Completed | Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection | Feb 07, 2021 | ― |
| Brii-196 And Brii-198 | Covid-19 | Phase I | Completed | A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 | Dec 17, 2020 | ― |
| Vir-2218 | Hepatitis B, Chronic | Phase II | Completed | Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China | Aug 07, 2020 | ― |
| Brii-196 | Covid-19 | Phase I | Completed | Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 | Jul 14, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Brii-835 (Vir-2218), Brii-179, Peg-Ifnα | Phase II | Chronic Hepatitis B Virus (Hbv) Infection | Recruiting | A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) | Oct 12, 2024 | ― |
| Brii-835 (Vir-2218), Brii-179, Peg-Ifnα | Phase II | For Treatment Of Chronic Hepatitis B Virus Infection | Active Not Recruiting | Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | Jun 28, 2024 | ― |
| Brii-296, Depo Medrol | Phase II | Severe Postpartum Depression | Completed | A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD) | Sep 21, 2023 | ― |
| Peg-Ifnα, Brii-835 | Phase II | Chronic Hepatitis B Virus Infection | Active Not Recruiting | Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients | Jul 21, 2023 | ― |
| Brii-297 | Phase I | Postpartum Depression | Completed | A Study of BRII-297 in Healthy Adult Subjects | Apr 12, 2023 | ― |
| Brii-196 And Brii-198 | Phase II | Covid-19 | Completed | A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 | Mar 04, 2021 | ― |
| Brii-835 (Vir-2218), Brii-179 (Vbi-2601) With Ifn-Α, Brii-179 (Vbi-2601) | Phase II | Hepatitis B, Chronic | Completed | Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection | Feb 07, 2021 | ― |
| Brii-196 And Brii-198 | Phase I | Covid-19 | Completed | A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 | Dec 17, 2020 | ― |
| Vir-2218 | Phase II | Hepatitis B, Chronic | Completed | Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China | Aug 07, 2020 | ― |
| Brii-196 | Phase I | Covid-19 | Completed | Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 | Jul 14, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Brii Biosciences Limited (HK:2137) have in its pipeline
Brii Biosciences Limited HK:2137 is currently developing the following drugs: Brii-835 (Vir-2218), Brii-179, Peg-Ifnα, Brii-296, Depo Medrol, Peg-Ifnα, Brii-835, Brii-297, Brii-196 And Brii-198, Brii-835 (Vir-2218), Brii-179 (Vbi-2601) With Ifn-Α, Brii-179 (Vbi-2601), Vir-2218, Brii-196, Brii-198. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

